Oncoimmunology

Article	Citations
Identification of pyroptosis-related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in colorectal cancer	77
Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer	73
PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity	55
Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies	54
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer	54
Ferroptosis becomes immunogenic: implications for anticancer treatments	53
Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer	52
Exosome-mediated communication between tumor cells and tumor-associated macrophages: implications for tumor microenvironment	49
YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non–small-cell lung cancer	48
Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative breast cancer	47
IFN-γ-induced ER stress impairs autophagy and triggers apoptosis in lung cancer cells	46
YKT6 , as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8+ T cell infiltration	45
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma	42
Lipid-associated macrophages in the tumor-adipose microenvironment facilitate breast cancer progression	39
Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity	38
Integrated analyses of m 1 A regulator-mediated modification patterns in tumor microenvironment-infiltrating immune cells in colon cancer	36
Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study	35
Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer	34
Tumors exploit CXCR4 hi CD62L lo aged neutrophils to facilitate metastatic spread	33
TIGIT + TIM-3 + NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related	33
Trial watch: intratumoral immunotherapy	33
Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients	33
Gas plasma irradiation of breast cancers promotes immunogenicity, tumor reduction, and an abscopal effect in vivo	33
The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis	33
Tumor-intrinsic determinants of immunogenic cell death modalities	31

Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis	31
Association between immune-related adverse event timing and treatment outcomes	31
Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer	31
Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors	30
Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma	30
LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells	30
Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer	30
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors	29
Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in lung adenocarcinoma	29
Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness	29
STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer	29
Neutrophil extracellular traps induce tumor metastasis through dual effects on cancer and endothelial cells	29
Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic drugs	29
Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer	28
Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry	28
Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine	28
Combination of EP 4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells	28
The role of irreversible electroporation in promoting M1 macrophage polarization via regulating the HMGB1-RAGE-MAPK axis in pancreatic cancer	28
Targeting stearoyl-coa desaturase enhances radiation induced ferroptosis and immunogenic cell death in esophageal squamous cell carcinoma	27
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression	27
Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic cancer	27
Chronic stress promotes breast carcinoma metastasis by accumulating myeloid-derived suppressor cells through activating β-adrenergic signaling	26
Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice	26
A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer	25
PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer	25
PD-1 blockade improves the anti-tumor potency of exhausted CD3 + CD56 + NKT-like cells in patients with primary hepatocellular car	25
Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis	25
Novel deep learning-based survival prediction for oral cancer by analyzing tumor-infiltrating lymphocyte profiles through CIBERSORT	25
PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy	25
Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer	24
M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer	24
CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma	24
The dark side of ferroptosis in pancreatic cancer	24
Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12	24
Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma	23
Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma	23
Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion	23
PD-L2 based immune signature confers poor prognosis in HNSCC	22
Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538	22
T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer	22
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data	22
Characterization of immune landscape in papillary thyroid cancer reveals distinct tumor immunogenicity and implications for immunotherapy	22
Discovery of immunogenic cell death-inducing ruthenium-based photosensitizers for anticancer photodynamic therapy	22
CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy	22
Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients	22
Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An	21
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers	21
PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma	21
Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma	21
Single-cell transcriptome analysis of CAR T-cell products reveals subpopulations, stimulation, and exhaustion signatures	21

Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity	21
Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors	21
Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers	21
Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma	21
Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer	21
VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma	21
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients	21
Cldn-7 deficiency promotes experimental colitis and associated carcinogenesis by regulating intestinal epithelial integrity	20
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure	20
Cross-reactivity between cancer and microbial antigens	20
Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis	20
Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner	20
Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer	20
Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma	20
Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma	20
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors	20
Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer	20
Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer	19
Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents	19
Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity	19
LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs	19
Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1	19
CXCL5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer CD8 T cells and limits the efficacy of checkpoint inhibitors	19
Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response	19
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study	19
IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer	19
Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma	18
PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells	18
Immunological alternation in COVID-19 patients with cancer and its implications on mortality	18
Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy	18
Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma	18
Early changes in the immune microenvironment of oral potentially malignant disorders reveal an unexpected association of M2 macrophages with oral cancer free survival	18
Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma	18
Immunotherapy approaches for the treatment of diffuse midline gliomas	18
Trial watch: chemotherapy-induced immunogenic cell death in oncology	18
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma	18
Increased frequency of TIGIT + CD73-CD8 + T cells with a TOX + TCF-1low profile in patients wit	18
TNFSF15 facilitates differentiation and polarization of macrophages toward M1 phenotype to inhibit tumor growth	18
An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy	18
Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer	18
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression	18
Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients	17
Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response	17
Single-cell profiling of infiltrating B cells and tertiary lymphoid structures in the TME of gastric adenocarcinomas	17
Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer	17
DIMEimmune: Robust estimation of infiltrating lymphocytes in CNS tumors from DNA methylation profiles	17
Alternol triggers immunogenic cell death via reactive oxygen species generation	17
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors	17
Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells	17
Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients	17
Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy	17
Double-edged effects of interferons on the regulation of cancer-immunity cycle	17
Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML	16
T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction	16
Spatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma	16
Phenotypic profiling and prognostic significance of immune infiltrates in esophageal squamous cell carcinoma	16
Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer	16
A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes	16
Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting	16
Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding	16
T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production	16
T and NK cell abundance defines two distinct subgroups of renal cell carcinoma	16
Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients	15
Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors	15
PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells	15
MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer	15
Tumor-associated macrophages promote intratumoral conversion of conventional CD4+ T cells into regulatory T cells via PD-1 signalling	15
Dissecting the heterogeneity of the microenvironment in primary and recurrent nasopharyngeal carcinomas using single-cell RNA sequencing	14
CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development	14
Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis	14
Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients	14
A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1	14
Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition	14
Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation	14
IFN-γ activates the tumor cell-intrinsic STING pathway through the induction of DNA damage and cytosolic dsDNA formation	14
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody	14
PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer	14
Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response	14
Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers	14
Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy	14

Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils	14
T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival	14